What Plegine Treats: Main Uses and Benefits

Plegine is commonly used as an adjunctive short-term treatment for exogenous obesity in adults and certain adolescents, often relevant in conditions marked by increased physiological stress based on high Body Mass Index thresholds. Its use is generally integrated into a comprehensive weight loss plan that involves a strict caloric restriction regimen and increased physical activity.

The medication provides support by helping to manage the symptom of excessive hunger and the persistent appetite drive. This helps patients cope more steadily with the required strict diet, easing the physical and psychological burden of persistent hunger and contributing to improved comfort during a challenging weight-reduction experience.

The therapeutic use generally covers exogenous obesity and clinical scenarios where patients have shown failure to respond to diet and exercise alone. By aiding in the achievement of a sustained calorie deficit during this crucial phase, the medication supports the primary therapeutic goal of weight reduction and may assist with maintaining functional stability concerning associated metabolic and cardiovascular conditions.

Quick Fact: Primary Symptom Focus: Excessive Appetite The medication is relevant for easing excessive hunger and appetite drive, which are the primary symptoms that may interfere with consistent adherence to a low-calorie diet.

Regulatory References

1. PHENDIMETRAZINE TARTRATE tablet - DailyMed - NIH

Who Can and Cannot Use Plegine?

The official eligibility criteria for Plegine (Phendimetrazine Tartrate) are strictly defined by regulatory labeling and dictate who may use the medicine and who must be excluded. Use is limited to the short-term adjunctive treatment of exogenous obesity.

Eligibility Criteria

Absolute Contraindications

Patients with the following conditions or states must not use Plegine, as noted in the regulatory label:

• Cardiovascular Disease: History of symptomatic cardiovascular disease, uncontrolled hypertension, or advanced arteriosclerosis.
• Endocrine/Ocular Conditions: Hyperthyroidism or glaucoma.
• Psychiatric: History of drug abuse or agitated states.
• Reproductive Status: Women who are pregnant or nursing (lactating).
• Drug Interaction: Use with or within 14 days of taking Monoamine Oxidase Inhibitors (MAOIs).

Age and Condition Restrictions

Use in patients under 17 years (pediatric) is not established for safety and effectiveness. The extended-release capsule is not recommended for this age group. Caution is required for geriatric patients and those with conditions such as mild hypertension, diabetes mellitus, or impaired renal function.

Interactions with other medicines and products

Plegine (phendimetrazine tartrate) is a sympathomimetic amine and its use is subject to several documented drug interactions, some of which are strictly contraindicated. The following information summarizes the official regulatory guidance on drug and substance interactions.

All patients should inform a healthcare professional of all prescription and non-prescription products, vitamins, and herbal supplements they are currently taking. Close monitoring may be required when Plegine is used alongside medications for high blood pressure or diabetes. The primary safety constraint is the mandatory 14-day gap required after stopping an MAOI to prevent a severe hypertensive reaction.

Plegine (Phendimetrazine) functions as a prodrug that is metabolized into the active sympathomimetic compound, Phenmetrazine. The mechanism of action is primarily executed by phenmetrazine acting as a Norepinephrine-Dopamine Releasing Agent ( NDRA). This molecule targets the Norepinephrine Transporter ( NET) and Dopamine Transporter ( DAT) on presynaptic nerve terminals, causing them to operate in reverse. This action forces the release of stored norepinephrine ( NE) and dopamine ( DA) into the synaptic cleft. The resulting surge of NE and DA in the hypothalamus directly modulates neural signaling that governs the sensation of satiety and hunger. This same monoamine-releasing effect extends to the autonomic nervous system, causing a systemic activation of adrenergic receptors that leads to the physiological consequences of increased heart rate and blood pressure. The central monoamine-releasing mechanism is susceptible to tachyphylaxis (rapid tolerance), where the drug’s ability to modulate signaling diminishes quickly due to the adaptation or depletion of releasable neurotransmitter stores.

How to Use Plegine (Phendimetrazine Tartrate): Administration Guidelines

Plegine is a prescription-only medication administered exclusively by the oral route and must be used strictly as a short-term adjunct to a comprehensive weight-reduction plan based on caloric restriction. The specific dosing regimen depends on the chosen dosage form.

Dosage and Scheduling

Standard initial dosing for the IR tablet is typically 35 mg (or potentially 17.5 mg) taken 2 or 3 times daily, not to exceed the established maximum. The ER capsule is a single daily dose.

Administration Requirements and Restrictions

To ensure proper release and effectiveness, the extended-release capsule must be swallowed whole and must not be crushed, broken, or chewed. This medication is authorized only for monotherapy; its use in combination with any other anorectic agents is prohibited by product labeling.

Treatment duration is limited, typically to a few weeks. If the patient develops tolerance to the appetite-suppressing effect, the medication should be discontinued rather than increasing the dosage past the maximum limit.

Population-Specific Dosing

Older adults (geriatric patients) require a cautious approach to dose selection, often starting at the lower end of the dosing range. For pediatric populations, the ER capsule is indicated for adolescents 17 years of age and older, while the safety and effectiveness of the IR tablet have not been established in those under 18 years.

Research Evidence / Overview of Studies for Plegine (Phendimetrazine Tartrate)

Evidence for Short-Term Weight Change in Adults with Obesity

Research exploring the use of Plegine has primarily centered on its designation as a short-term adjunct in the research exploration of obesity for adults. The main research approach studies explored short-term Randomized Controlled Trials (RCTs). These studies were structured to compare the use of Plegine, combined with a strict calorie-restricted diet and exercise plan, against a placebo combined with the same diet and exercise plan. Researchers specifically examined outcomes related to change in body weight and Body Mass Index (BMI) over the limited period of the trials.

The findings describe patterns observed in the studies. Studies reported measurements where the average change in body weight was numerically different between the group receiving Plegine plus diet and the group receiving placebo plus diet over the limited duration studied. This outcome, however, was monitored only over a limited duration. Research describes that the studies monitored a difference in the rate of weight change that findings indicated was a small amount per week between the two groups. Research also highlights that total weight change observed in patients was found to be highly variable, suggesting outcomes are influenced by individual factors and the dietary plan.

Comparison in Trials: Drug vs. Placebo and Diet

These studies monitored specific groups of adults, typically those with an initial BMI of 30 kg/m^2 or higher, or a BMI of 27 kg/m^2 or higher in the presence of associated obesity-related conditions. Regulatory reviews noted the difference in the amount of weight reported between the two comparison groups was small. Research describes patterns where time-related findings indicate that the observed effects may appear to diminish or decline the longer the medication was observed in the short study intervals.

Evidence in Pediatric and Adolescent Populations

Official regulatory reviews indicate that research data are insufficient to establish use in patients under the age of 17 years. While some data was observed in adolescents (aged 17 and older), research for this group remains significantly limited. Furthermore, the research that exists mainly was studied for long-term physiological data in younger populations. Currently, data for certain groups remain insufficient.

Key Studies & References

1. PHENDIMETRAZINE TARTRATE tablet - DailyMed

Common questions about Plegine (FAQ)

Q: How quickly does Plegine typically start working?

A: Official pharmacokinetic studies (which examine how the body processes the drug) provide information on the time to maximum concentration ( Tmax) of the active compound. This timeframe may vary significantly based on whether the immediate-release tablet or the extended-release capsule is used.

Q: What is the typical timeframe before the full effect of Plegine is noticed?

A: Regulatory pharmacokinetic data describes the time to maximum concentration ( Tmax) of the active compound following administration. This data, which correlates with the onset of effect, suggests the timeframe may vary depending on the dosage form used (immediate-release or extended-release).

Q: What should I do if I miss a dose of Plegine?

A: Official patient guidance on managing a missed dose generally describes the acceptable window for taking the forgotten amount or the conditions under which it should be skipped. Since Plegine is a controlled substance, this guidance is crucial for maintaining a consistent treatment regimen.

Q: Can Plegine be taken with pain relievers like ibuprofen or aspirin?

A: Official labeling advises patients to inform their healthcare professional of all prescription, non-prescription products, vitamins, and supplements they are currently taking. This information is necessary for a healthcare professional to assess the risk of potential interactions, including with common pain relievers, prior to initiating treatment.

Q: Does Plegine interact with birth control pills?

• Official regulatory documents contain a specific list of known drug interactions and contraindications. This formal interaction list does not include specific warnings or statements regarding hormonal oral contraceptives (birth control pills).

Q: Are there any common foods or drinks that should be avoided when using Plegine?

A: Official product information strongly advises against the use of alcohol with Plegine, as combining them may result in an adverse drug reaction. Beyond this, the medication is intended to be used only as an aid to a comprehensive, calorie-restricted diet plan.

Q: Is it safe to drive or operate machinery after taking Plegine?

A: Regulatory warnings state that Plegine may impair a person's judgment, thinking, or motor skills. Therefore, official documents advise patients to avoid driving a vehicle or operating hazardous machinery until they know how the medication affects them.

Q: Can Plegine be split in half if it's a tablet?

A: Official administration instructions specify that the extended-release capsule must be swallowed whole and should not be crushed or chewed. The administration requirements for the immediate-release tablet form are based on the prescribed dose strength, and specific instructions for splitting should be confirmed by a healthcare professional.

Q: What happens if I accidentally take too much Plegine?

A: Official documentation provides a specific section detailing the signs and symptoms of acute overdosage. These symptoms are described as potentially including severe reactions like restlessness, confusion, rapid breathing, and hyperthermia (dangerously elevated body temperature).

Q: What should I look out for as a potential allergic reaction to Plegine?

A: Regulatory documents list all reported adverse reactions but do not specifically categorize or detail common Type I allergic symptoms, such as rash or anaphylaxis. The official label indicates that symptoms of any serious adverse reaction warrant immediate medical attention.

Q: What are the known risks of suddenly stopping Plegine?

A: Official documents on drug dependence note that Plegine has a potential for abuse. If the medication is stopped suddenly after prolonged, high-dose use, it may lead to withdrawal symptoms. These symptoms are described as including extreme fatigue and mental depression.

Q: Is it normal to feel [vague side effect like fatigue/dizziness] when first starting Plegine?

A: Regulatory labeling lists dizziness, restlessness, and nervousness as commonly reported side effects. However, official information does not specify a typical timeframe for when these effects may occur after beginning the medicine.

Q: How do the benefits of Plegine generally compare to the potential risks?

A: Plegine is officially indicated only for the short-term treatment of obesity. This time limit aligns with regulatory warnings which describe that the potential for serious adverse reactions, such as severe heart and lung problems, may increase with prolonged use of the drug.

Q: Are the safety warnings for Plegine different for men and women?

A: Official safety warnings include specific contraindications for women who are pregnant or are currently nursing (lactating). Outside of these reproductive considerations, the other general safety warnings and precautions described in the regulatory documents apply equally to all adults.

Q: Is Plegine affected by exposure to heat or cold?

A: Official storage requirements specify that the medication must be maintained at a Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Maintaining the medicine within this defined range is recommended to ensure the product’s quality and stability.

Q: Are generic versions of Plegine available?

A: The active ingredient, phendimetrazine tartrate, is officially listed in regulatory databases of approved drug products. This listing indicates that generic versions of the medicine are authorized and available for use.

Q: Are there different brand names for the medicine Plegine?

A: Official regulatory records contain a list of multiple brand names that are authorized to market the active ingredient phendimetrazine tartrate. Plegine is one of several products containing this active ingredient.

Q: What is the role of the inactive ingredients in Plegine?

A: Official documents list the name of every inactive ingredient (also called excipients) contained in the medication alongside the active phendimetrazine tartrate. These are necessary components for the manufacturing, stability, and proper function of the solid oral dosage form.

Q: How is Plegine eliminated from the body?

A: Pharmacokinetic studies show that the drug is primarily processed and eliminated from the body by the kidneys, a process known as renal excretion. The elimination half-life is a key factor that contributes to the drug’s duration of effect.

Q: Are there any clinical trials currently recruiting for Plegine?

A: Information regarding any ongoing clinical research and recruiting trials for phendimetrazine tartrate is a matter of public record. This status can be confirmed by searching official government-sponsored clinical trial registries.

Q: What should be done if an interaction with another medicine is suspected while taking Plegine?

A: Official patient counseling information emphasizes that symptoms of serious adverse reactions or suspected drug interactions, such as those that could potentially lead to a hypertensive crisis, require immediate medical attention.

Q: Can people with liver problems use Plegine?

A: Official regulatory documents describe the metabolism of the drug in the body. However, official labeling does not specifically list hepatic impairment (liver problems) as an absolute contraindication or require mandatory dosage adjustments in this population.

How to Store and Dispose of Plegine

Official Storage Requirements

Plegine (phendimetrazine tartrate) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. Official labeling requires the medication to be dispensed and maintained in a tight, light-resistant container to ensure protection from moisture and light. It is a mandatory child safety requirement to keep Plegine out of the sight and reach of children and use a child-resistant closure.

Disposal Instructions

As this medication is a controlled substance and is not on the FDA's flush list, unused or expired Plegine must be disposed of via secure means. The preferred method is using an official drug take-back program. If a take-back program is unavailable, the product must be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container before being discarded in the household trash.